Dynavax Technologies Corporation (NASDAQ:DVAX) – Equities researchers at William Blair issued their Q1 2018 earnings per share (EPS) estimates for Dynavax Technologies Corporation in a research note issued to investors on Monday. William Blair analyst Y. Xu anticipates that the biopharmaceutical company will post earnings of ($0.17) per share for the quarter. William Blair has a “Outperform” rating and a $30.00 price objective on the stock. William Blair also issued estimates for Dynavax Technologies Corporation’s Q2 2018 earnings at ($0.11) EPS, Q3 2018 earnings at ($0.02) EPS and Q4 2018 earnings at $0.09 EPS.

A number of other brokerages also recently issued reports on DVAX. Cantor Fitzgerald began coverage on Dynavax Technologies Corporation in a research report on Friday, September 15th. They set an “overweight” rating and a $24.00 price objective on the stock. Royal Bank Of Canada restated an “outperform” rating and set a $28.00 price objective (up from $26.00) on shares of Dynavax Technologies Corporation in a research report on Monday, September 25th. ValuEngine upgraded Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, September 7th. Cowen and Company restated an “outperform” rating and set a $30.00 price objective on shares of Dynavax Technologies Corporation in a research report on Thursday, August 10th. Finally, Zacks Investment Research upgraded Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Dynavax Technologies Corporation has a consensus rating of “Buy” and a consensus price target of $25.00.

ILLEGAL ACTIVITY NOTICE: “Analysts Offer Predictions for Dynavax Technologies Corporation’s Q1 2018 Earnings (DVAX)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/05/analysts-offer-predictions-for-dynavax-technologies-corporations-q1-2018-earnings-dvax.html.

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) traded down 0.5532% during mid-day trading on Tuesday, hitting $23.8175. 494,028 shares of the stock were exchanged. The firm has a 50-day moving average price of $19.38 and a 200 day moving average price of $11.00. The company’s market capitalization is $1.30 billion. Dynavax Technologies Corporation has a 12-month low of $3.20 and a 12-month high of $24.20.

Dynavax Technologies Corporation (NASDAQ:DVAX) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. The business had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.15 million. During the same period in the previous year, the company earned ($0.75) earnings per share.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. GMT Capital Corp grew its stake in shares of Dynavax Technologies Corporation by 28.2% during the second quarter. GMT Capital Corp now owns 3,005,137 shares of the biopharmaceutical company’s stock valued at $29,450,000 after buying an additional 660,637 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Dynavax Technologies Corporation by 10.9% during the second quarter. Vanguard Group Inc. now owns 2,024,666 shares of the biopharmaceutical company’s stock valued at $19,538,000 after buying an additional 199,004 shares during the last quarter. PointState Capital LP bought a new position in shares of Dynavax Technologies Corporation during the second quarter valued at approximately $13,510,000. Kornitzer Capital Management Inc. KS grew its stake in shares of Dynavax Technologies Corporation by 4.0% during the second quarter. Kornitzer Capital Management Inc. KS now owns 1,142,360 shares of the biopharmaceutical company’s stock valued at $11,024,000 after buying an additional 43,850 shares during the last quarter. Finally, State Street Corp grew its stake in shares of Dynavax Technologies Corporation by 19.7% during the second quarter. State Street Corp now owns 839,218 shares of the biopharmaceutical company’s stock valued at $8,099,000 after buying an additional 138,112 shares during the last quarter. 60.20% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Earnings History and Estimates for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Stock Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related stocks with our FREE daily email newsletter.